Myeloma Investment Fund Invests in Reverb Therapeutics to Support Debut of its Amplifier™ Platform for Redirecting Endogenous Cytokines

November 15, 2023

The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Reverb Therapeutics to explore the potential of its antibody-based Amplifier™ platform for the treatment of multiple myeloma with endogenous cytokines that naturally occur within the body.